Sale!

SLC25A22 Gene Early infantile epileptic encephalopathy type 3 Genetic Test

3,200 د.إ

-43%

The SLC25A22 gene is associated with early infantile epileptic encephalopathy type 3 (EIEE3), a severe form of epilepsy that begins in infancy. This condition is characterized by frequent seizures and significant neurodevelopmental delay. The SLC25A22 gene plays a crucial role in the proper functioning of mitochondria, the energy-producing components of cells, and mutations in this gene can disrupt brain activity, leading to the symptoms observed in EIEE3.

Genetic testing for mutations in the SLC25A22 gene is a critical step in diagnosing EIEE3, enabling early intervention and tailored management plans for affected infants. DNA Labs UAE offers a comprehensive genetic test for the SLC25A22 gene to help identify the presence of mutations associated with early infantile epileptic encephalopathy type 3. The test cost is 3200 AED and is conducted with state-of-the-art technology to ensure accurate and reliable results. By undergoing this test, families can gain valuable insights into the genetic underpinnings of the condition, which can inform treatment decisions and provide a clearer prognosis for affected infants.

Home  Sample collection service available

  • 100% accuaret Test Results
  • Ranked as Most trusted Genetic DNA Lab
  • This test is not intended for medical diagnosis or treatment
Guaranteed Safe Checkout

SLC25A22 Gene Early Infantile Epileptic Encephalopathy Type 3 Genetic Test

Overview

The SLC25A22 gene is associated with Early infantile epileptic encephalopathy type 3 (EIEE3), a rare genetic disorder that affects the brain and causes seizures. This disorder typically begins in the first few months of life and is characterized by recurrent seizures, developmental delay, and intellectual disability.

Test Details

The SLC25A22 Gene Early Infantile Epileptic Encephalopathy Type 3 Genetic Test is a neurology-based genetic test offered by DNA Labs UAE. The test uses NGS (Next Generation Sequencing) technology to identify mutations in the SLC25A22 gene that are associated with EIEE3.

Components

  • Price: 3200.0 AED
  • Sample Condition: Blood or Extracted DNA or One drop Blood on FTA Card
  • Report Delivery: 3 to 4 Weeks
  • Method: NGS Technology
  • Test Type: Neurological Disorders
  • Doctor: Neurologist
  • Test Department: Genetics

Pre Test Information

Before undergoing the SLC25A22 Gene Early Infantile Epileptic Encephalopathy Type 3 Genetic Test, it is important to provide the clinical history of the patient. Additionally, a genetic counseling session may be conducted to draw a pedigree chart of family members affected with EIEE3.

Procedure

The SLC25A22 Gene Early Infantile Epileptic Encephalopathy Type 3 Genetic Test requires a sample of the patient’s DNA. This can be obtained through a blood sample or a cheek swab. The DNA is then sequenced using NGS technology to identify any mutations in the SLC25A22 gene.

Implications and Treatment

If a mutation is identified, genetic counseling may be recommended to help the patient and their family understand the implications of the diagnosis. Treatment for EIEE3 typically involves medications to control seizures and supportive therapies to address developmental delays and other symptoms.

Test Name SLC25A22 Gene Early infantile epileptic encephalopathy type 3 Genetic Test
Components
Price 3200.0 AED
Sample Condition Blood or Extracted DNA or One drop Blood on FTA Card o
Report Delivery 3 to 4 Weeks
Method NGS Technology
Test type Neurological Disorders
Doctor Neurologist
Test Department: Genetics
Pre Test Information Clinical History of Patient who is going for SLC25A22 Gene Early infantile epileptic encephalopathy type 3 NGS Genetic DNA Test A Genetic Counselling session to draw a pedigree chart of family members affected with SLC25A22 Gene Early infantile epileptic encephalopathy type 3
Test Details

The SLC25A22 gene is associated with Early infantile epileptic encephalopathy type 3 (EIEE3), a rare genetic disorder that affects the brain and causes seizures. This disorder typically begins in the first few months of life and is characterized by recurrent seizures, developmental delay, and intellectual disability.

NGS (Next Generation Sequencing) genetic testing is a type of genetic testing that uses advanced technology to rapidly sequence large amounts of DNA. This type of testing can be used to identify mutations in the SLC25A22 gene that are associated with EIEE3.

NGS genetic testing for EIEE3 typically involves collecting a sample of the patient’s DNA, which can be obtained through a blood sample or a cheek swab. The DNA is then sequenced using NGS technology to identify any mutations in the SLC25A22 gene.

If a mutation is identified, genetic counseling may be recommended to help the patient and their family understand the implications of the diagnosis and to discuss any treatment options that may be available. Treatment for EIEE3 typically involves medications to control seizures and supportive therapies to address developmental delays and other symptoms.